TY - JOUR
T1 - Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate
T2 - a case study
AU - Filgueira, Carly S.
AU - Bruno, Giacomo
AU - Smith, Zachary W.
AU - Chua, Corrine Ying Xuan
AU - Ballerini, Andrea
AU - Folci, Marco
AU - Gilbert, April L.
AU - Jain, Priya
AU - Sastry, Jagannadha K.
AU - Nehete, Pramod N.
AU - Shelton, Kathryn A.
AU - Hill, Lori R.
AU - Ali, Areeba
AU - Youker, Keith A.
AU - Grattoni, Alessandro
N1 - Funding Information:
Acknowledgements The authors would like to acknowledge Drs. Kevin Phillips, Jean Lin, Paul Webb, Eugenia Nicolov, and Omaima Sabek for early discussions and project developments, Carlos Favela and Dr. Kemi Cui from the advanced cellular and tissue microscopy core, Dr. Andreana Rivera, Sandra Steptoe, and Dr. Yuelan Ren from the research pathology core. We also thank Dr. Greg Wilkerson, Luke Segura, Elizabeth Lindemann, and Debra Larsen from the Michale E. Keeling Center for Comparative Medicine and Research at MD Anderson Cancer Center, Dr. Yongying Jiang from the Pharmaceutical Science Facility, Institute of Applied Cancer Science, UT MD Anderson Cancer Center, and Dr. Jingfei Ma, Lindsay Wilson, and Michelle Underwood from MD Anderson Cancer Center. Membranes were provided by NanoMedical Systems, Inc. This work was supported by funds from Houston Methodist Research Institute (AG).
Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - With nearly 40% of U.S. adults obese, and childhood and adolescent rates rising, obesity and associated comorbidities are serious public health concerns with massive societal costs. Often, lifestyle interventions do not offer sufficient weight loss to improve health, requiring surgery and medications as adjunct management strategies. Here, we present a 4-month case study in which the sustained, low-dose, and constant administration of the thyroid receptor β selective agonist GC-1 (sobetirome) from a novel nanochannel membrane implant was assessed in an obese, pre-diabetic rhesus macaque. Dramatic loss of white adipose tissue in the abdomen from 36 to 18% was observed via magnetic resonance imaging in conjunction with normalized serum insulin and glycemia, with no signs of cardiotoxicity shown. The non-human primate study highlights sustained low-dose delivery of GC-1 from our minimally invasive subcutaneous implant as a valuable approach to induce weight loss and manage obesity and comorbidities, including type 2 diabetes.
AB - With nearly 40% of U.S. adults obese, and childhood and adolescent rates rising, obesity and associated comorbidities are serious public health concerns with massive societal costs. Often, lifestyle interventions do not offer sufficient weight loss to improve health, requiring surgery and medications as adjunct management strategies. Here, we present a 4-month case study in which the sustained, low-dose, and constant administration of the thyroid receptor β selective agonist GC-1 (sobetirome) from a novel nanochannel membrane implant was assessed in an obese, pre-diabetic rhesus macaque. Dramatic loss of white adipose tissue in the abdomen from 36 to 18% was observed via magnetic resonance imaging in conjunction with normalized serum insulin and glycemia, with no signs of cardiotoxicity shown. The non-human primate study highlights sustained low-dose delivery of GC-1 from our minimally invasive subcutaneous implant as a valuable approach to induce weight loss and manage obesity and comorbidities, including type 2 diabetes.
KW - GC-1
KW - Non-human primate
KW - Sobetirome
KW - Sustained release
KW - Thyroid hormone mimetics
UR - http://www.scopus.com/inward/record.url?scp=85048726214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048726214&partnerID=8YFLogxK
U2 - 10.1007/s10544-018-0296-2
DO - 10.1007/s10544-018-0296-2
M3 - Article
C2 - 29916059
AN - SCOPUS:85048726214
SN - 1387-2176
VL - 20
JO - Biomedical Microdevices
JF - Biomedical Microdevices
IS - 2
M1 - 49
ER -